Introduction: Cariprazine, a dopamine D-preferring D/D receptor partial agonist and serotonin 5-HT receptor partial agonist, has two major human metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR). The metabolite pharmacology was profiled to understand the contribution to cariprazine efficacy.
Methods: In vitro receptor binding and functional assays, electrophysiology, animal models, microdialysis, and kinetic-metabolism approaches were used to characterize the pharmacology of DCAR and DDCAR.
Cariprazine {RGH-188; trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-N',N'-dimethylurea hydrochloride}, a novel candidate antipsychotic, demonstrated approximately 10-fold higher affinity for human D(3) versus human D(2L) and human D(2S) receptors (pKi 10.07, 9.16, and 9.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
November 2008
RG-15 (trans-N-[4-[2-[4-(3-cyano-5-trifluoromethyl-phenyl)-piperazine-1-yl]-ethyl]-cyclohexyl]-3-pyridinesulfonic amide dihydrochloride) displayed subnanomolar affinity to human and rat dopamine D3 receptors (pKi 10.49 and 9.42, respectively) and nanomolar affinity to human and rat D2 receptors (pKi 8.
View Article and Find Full Text PDFBackground And Purpose: Low-dose irradiation and suboptimal drug concentrations may induce unexpected biological responses. Paclitaxel (PTX) is a widely used drug, which has a range of antitumoral effects and which is also regarded as a radiation sensitizer. In this study, it was tested how "suboptimal" short exposure to PTX modifies the biological effects of low-dose irradiation on human epithelial carcinoma cell lines.
View Article and Find Full Text PDF